Zeke Capital Advisors LLC Invests $258,000 in Teva Pharmaceutical Industries Ltd (TEVA) Stock

Zeke Capital Advisors LLC acquired a new position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 13,638 shares of the company’s stock, valued at approximately $258,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TEVA. Calton & Associates Inc. purchased a new stake in Teva Pharmaceutical Industries in the 4th quarter worth approximately $108,000. Fieldpoint Private Securities LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $171,000. Global Financial Private Capital LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $193,000. Wetherby Asset Management Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $197,000. Finally, Sigma Planning Corp purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $214,000. Institutional investors and hedge funds own 58.19% of the company’s stock.

How to Become a New Pot Stock Millionaire

TEVA has been the subject of a number of research analyst reports. ValuEngine upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Tuesday, December 5th. Jefferies Group initiated coverage on Teva Pharmaceutical Industries in a research note on Tuesday. They issued a “hold” rating and a $19.00 target price for the company. Wells Fargo restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Saturday, November 25th. Zacks Investment Research cut Teva Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research note on Friday, January 12th. Finally, Credit Suisse Group upgraded Teva Pharmaceutical Industries from an “underperform” rating to a “neutral” rating and raised their target price for the company from $8.00 to $20.00 in a research note on Friday, December 15th. Ten analysts have rated the stock with a sell rating, fifteen have issued a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $20.69.

In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 5,050 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $19.68, for a total value of $99,384.00. Following the completion of the sale, the executive vice president now owns 44,517 shares of the company’s stock, valued at approximately $876,094.56. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 10,734 shares of company stock valued at $204,795. Corporate insiders own 7.10% of the company’s stock.

TEVA stock traded down $0.23 during trading on Wednesday, hitting $17.68. The company’s stock had a trading volume of 14,399,867 shares, compared to its average volume of 16,915,479. The company has a market cap of $18,212.27, a price-to-earnings ratio of -1.09, a price-to-earnings-growth ratio of 1.56 and a beta of 0.65. Teva Pharmaceutical Industries Ltd has a twelve month low of $10.85 and a twelve month high of $33.82. The company has a current ratio of 0.86, a quick ratio of 0.58 and a debt-to-equity ratio of 1.91.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, February 8th. The company reported $0.91 EPS for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.14. The business had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.29 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The company’s quarterly revenue was down 15.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.38 EPS. research analysts expect that Teva Pharmaceutical Industries Ltd will post 2.3 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Zeke Capital Advisors LLC Invests $258,000 in Teva Pharmaceutical Industries Ltd (TEVA) Stock” was reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.themarketsdaily.com/2018/03/21/zeke-capital-advisors-llc-invests-258000-in-teva-pharmaceutical-industries-ltd-teva-stock.html.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply